Connect with us

Technology

Condor Software Unveils World’s First Clinical Finance AI Agent Purpose-Built for Biopharma R&D

Published

on

New agent marks major expansion of Condor’s AI platform, enables biopharma R&D teams to ask complex questions about their clinical programs, and instantly get answers they can act on

SAN DIEGO, Sept. 17, 2026 /PRNewswire/ — Condor, the AI platform for biopharma R&D teams, today unveiled its new clinical finance agent that gives R&D teams the “why” behind variances, runs full what-if scenario planning, and then builds the resulting model directly in Condor. It’s part of a team of agents built on Condor’s clinical and financial ontology and knowledge graph with the Big 4 accounting and consulting firms. The agents automate workflows so R&D teams can make clinical and financial decisions more quickly and confidently.

Condor’s announcement comes as looming patent cliffs across the pharmaceutical industry intensify pressure on companies to replenish their pipelines. While AI has accelerated drug discovery and increased the number of viable candidates, the financial infrastructure drug development runs on remains remarkably manual and labor intensive. When a budget, forecast, and actuals diverge, R&D teams can lose hours, if not days, reconciling data across ERPs, CTMS, EDC systems, and spreadsheets to better understand the financial impact behind the “why”. Lagging decisions have real consequences — like continuing to fund an underperforming site, discovering a change-order problem after negotiations are already underway, or waiting weeks to understand the financial implications of an enrollment change.

The clinical finance agent reasons across an organization’s full budget and forecast history in Condor to explain the “why” behind the numbers, identifying in seconds rather than hours what’s driving a variance between actuals and forecast or the cost to complete a given trial. It also runs full what-if scenario planning, modeling changes to site mix, enrollment timing, or financial investment, and then builds the resulting model directly in the platform. Powered by Condor’s proprietary knowledge graph and a deterministic math layer with AI reasoning on top, the agent is tuned to how R&D teams actually ask questions; not generic corporate forecasting logic. Additionally capabilities will be added to the agent soon.

Here’s how the agent works: you ask the questions that used to take your team weeks to prepare, and instantly get answers you can act on. For example, an R&D team’s clinical operations or finance leader can ask:

“Which sites in this trial are falling behind, and what does that mean for my budget, timeline, and enrollment?” Condor identifies the sites creating risk and connects their performance to the downstream impact on enrollment, timing, and cost.

“What will it cost to complete enrollment?” Condor calculates a cost-to-complete forecast based on the current state of the trial, without waiting weeks for a team to manually rebuild the model.

“Why did my change order increase?” Condor traces the increase back to the clinical and operational activity driving it and identifies where there may be an opportunity to reduce the cost.

To see the agent in action, book a demo at https://condorsoftware.com/contact.

The clinical finance agent is one of several agents in Condor AI Workflows — one of Condor’s three product pillars. Condor Connect automatically centralizes clinical, operational, and financial data with an understanding of a biopharma’s processes. Condor AI Workflows then automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management. Condor AI Insights then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers.

Supporting Quotes

“Drug development runs on two things: the science and the money that funds it. For decades, science was the bottleneck. AI and the patent cliff are closing that gap, and pipelines are about to fill with more candidates than this industry has ever had to fund. But the bottleneck didn’t disappear. It moved from the lab to the ledger. Every one of those candidates still has to be forecasted, funded, and managed, and the financial infrastructure doing that job still runs on spreadsheets. The pharmaceutical industry doesn’t have a data problem. It has a context problem. Companies have more data than they’ve ever had. But answering a basic question like ‘Why did this trial get more expensive?’ can still require people to hunt across multiple systems and rebuild the answer manually. We started Condor to eliminate that gap, and our new clinical finance agent takes us one huge step closer to realizing our mission of giving biopharma R&D teams the information they need to make clinical and financial decisions quickly and confidently.”

—Condor Founder and CEO Jen Kyle

“Quickly producing the ‘why’ behind the numbers is the biggest pain point that clinical operations and FP&A teams experience. Any system can tell you you’re five million over budget. That’s not useful on its own. You need to know in a clinical context what’s actually driving it, and you need to know fast. Our knowledge graph lets us answer that in a way generic AI can’t, because it intimately understands the context underpinning the clinical trial activities. And it doesn’t stop at the answer; it also builds the model. Our clinical finance agent is one of many Condor AI agents, each purpose-built to remove a specific piece of the manual work that slows R&D teams down.”

— Condor VP of Product Nim Fox

About Condor Software

Condor Software is the AI platform for biopharma R&D teams. It automatically centralizes clinical, operational, and financial data; automates various workflows — like budgeting, forecasts, month-end closes, accruals, and change order management; and then surfaces patterns, flags risks, bridges context across functions, and delivers the “why” behind the numbers. Founded by Jen Kyle, Condor is backed by Insight Partners, Felicis, 645 Ventures, Pamir Ventures, and SNR Ventures, and is trusted by leading biopharma companies worldwide — including Acadia Pharmaceuticals, BridgeBio Pharma, Madrigal Pharmaceuticals, and Stemline Therapeutics. Learn more at condorsoftware.com.

Media Contact:
Joseph Roualdes
joseph.roualdes@condorsoftware.com
415.823.2136

View original content to download multimedia:https://www.prnewswire.com/news-releases/condor-software-unveils-worlds-first-clinical-finance-ai-agent-purpose-built-for-biopharma-rd-302879994.html

SOURCE Condor Software

Continue Reading

Technology

Teledyne LeCroy Announces PCI Express® 7.0 Protocol Exerciser

Published

on

By

Industry first standalone PCIe® 7.0 Protocol Exerciser, extends the Summit M616 Protocol Analyzer to deliver a complete validation and debug solution

MILPITAS, Calif., Sept. 17, 2026 /PRNewswire/ — Teledyne LeCroy, the worldwide leader in protocol test solutions, today announced the release of the Summit™ Z74 Protocol Exerciser for PCI Express® (PCIe®) 7.0 technology, designed to accelerate the development, validation, and debug of next-generation PCIe devices and systems. Summit Z74 operates as a standalone protocol exerciser for controlled traffic generation, or pairs with the Summit M616 Protocol Analyzer to create a complete PCIe 7.0 analysis and exerciser solution. Together, the platforms give engineering teams the control and visibility needed to expose interoperability issues earlier, shorten debug cycles, and reduce development risk.

Artificial intelligence, machine learning, high-performance computing (HPC), cloud infrastructure, and advanced storage applications are driving the demand for faster, lower-latency interconnects. To meet that demand, PCIe 7.0 specification doubles the raw data rate of PCIe 6.0 specification from 64.0 GT/s to 128.0 GT/s and delivers up to 512 GB/s of bi-directional bandwidth in a x16 configuration. At these speeds, Pulse Amplitude Modulation 4-level (PAM4) signaling, FLIT-based protocol, and increasingly complex system architectures require validation tools that can generate precise protocol traffic, emulate real-world workloads, reproduce problem conditions, and provide deterministic control over PCIe link behavior throughout the development lifecycle.

The Summit Z74 addresses these challenges with a flexible architecture for PCIe 7.0 technology development. Used independently, it enables engineers to generate controlled protocol traffic, exercise device behavior, and validate responses under targeted conditions. Paired with the Summit M616 Protocol Analyzer, the Summit Z74 becomes part of a comprehensive debug and validation system that combines traffic generation with deep protocol capture, decode, analysis, and debug. This solution enables engineering teams to efficiently isolate, resolve and verify link training behavior, transaction-level issues, protocol errors, LTSSM transitions, interoperability challenges, and compliance-development concerns within an industry-leading and customer familiar Summit workflow.

“The rapid evolution of PCI Express technology to the PCIe 7.0 specification is enabling new levels of performance for AI, storage, and high-performance computing applications,” said Al Yanes, PCI-SIG President and Chairperson. “Protocol test equipment accelerates validation and ecosystem readiness to help engineers address growing system complexity.”

“The Summit Z74 extends our long-standing commitment to the PCIe design and test community,” said Michael Romm, General Manager, Teledyne LeCroy Protocol Solutions Group. “Engineering teams can deploy the industry’s first standalone PCIe 7.0 protocol exerciser or pair it with the Summit M616 to create a complete, familiar environment for traffic generation, protocol visibility, validation, and debug. This flexibility helps customers protect their test investment while confidently advancing next-generation PCIe designs.”

Availability

The Summit Z74 and the Summit M616 are available to PCI Express technology development teams preparing for PCIe 7.0 specification validation programs. Please contact Teledyne LeCroy for additional product information, technical specifications, configuration guidance, and availability details.

For more information about Teledyne LeCroy PCI Express protocol analyzers, exercisers, interposers, and compliance solutions, contact Teledyne LeCroy at +1 (800) 909-7211 or visit https://www.teledynelecroy.com.

About Teledyne LeCroy

Teledyne LeCroy is a leading manufacturer of advanced oscilloscopes, protocol analyzers, and other test instruments that verify performance, validate compliance, and debug complex electronic systems quickly and thoroughly. Since its founding in 1964, the Company has focused on incorporating powerful tools into innovative products that enhance “Time-to-Insight”. Faster time to insight enables users to rapidly find and fix defects in complex electronic systems, dramatically improving time-to-market for a wide variety of applications and end markets. Teledyne LeCroy is based in Chestnut Ridge, N.Y. For more information, visit Teledyne LeCroy’s website at teledynelecroy.com.

About PCI-SIG
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of 1,000 industry-leading member companies. To join PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com.

© 2026 by Teledyne LeCroy. All rights reserved. Specifications are subject to change without notice. PCI-SIG, PCIe and PCI Express are registered trademarks of PCI-SIG. Summit, CATC Trace, and Teledyne LeCroy are trademarks or registered trademarks of Teledyne LeCroy, Inc. All other trademarks are the property of their respective owners.

Technical contact: Gordon Getty – Senior Director of Product Management 408-273-5673
Customer contact: Teledyne LeCroy PSG Customer Care Center 800-909-7211
Website: https://www.teledynelecroy.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/teledyne-lecroy-announces-pci-express-7-0-protocol-exerciser-302882262.html

SOURCE Teledyne LeCroy

Continue Reading

Technology

InventHelp Inventor Develops New Privacy & Security Product for Electronic Devices (TLS-1389)

Published

on

By

PITTSBURGH, Sept. 17, 2026 /PRNewswire/ — “I wanted to create a safe and secure way to use a computer, scroll through your phone, or watch television without compromising privacy or falling victim to cyber predators,” said an inventor, from Lakeland, Fla., “so I invented ONE FACE PRIVACY. My design prevents your privacy from being compromised, which could help solve numerous types of cyber victim issues.”

The patent-pending invention provides an effective way to increase privacy when using an electronic device. It also protects against cyber predators. As a result, it increases privacy, security, and safety. Additionally, it provides added protection and peace of mind. The invention features a unique design that is easy to use so it is ideal for households, owners and users of electronic devices, children, teens, etc.

The original design was submitted to the Tallahassee sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 25-TLS-1389, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp’s Invention Submission Services at http://www.InventHelp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/inventhelp-inventor-develops-new-privacy–security-product-for-electronic-devices-tls-1389-302876084.html

SOURCE InventHelp

Continue Reading

Technology

Zillow Preview℠ listings are now live on Realtor.com®, offering the same early access on the two most-visited real estate platforms in the country

Published

on

By

SEATTLE and AUSTIN, Texas, Sept. 17, 2026 /PRNewswire/ — Zillow® and Realtor.com® today announced that Preview℠ is live on both sites, bringing pre-market homes to buyers across the two most-visited real estate platforms in the country. No special login or brokerage relationship required. The same early access for every buyer, on both platforms starting today.

This marks the realization of a collaboration announced in May, and the largest pre-market syndication effort in U.S. residential real estate. Whether searching on Zillow or Realtor.com®, buyers will now see pre-market listings at the same time — clearly labeled as Preview listings, with no insider track required.

“Today we set a new standard for pre-market transparency on Zillow and Realtor.com®,” said Christopher Roberts, Zillow’s chief product officer. “While others in this industry are moving in the other direction and restricting early listings to private networks, we’re proving that broad, public visibility is better for sellers, better for buyers and better for agents.”

“It takes a shared commitment to bring two platforms to the table, but on this, we agree: an open marketplace serves buyers and sellers better than a closed one,” said Anna Marie Castiglioni, Head of Realtor.com® Next. “Bringing Preview Listings to both platforms means every buyer, on either site, gets access to the same homes at the same time — and every seller gets the benefit of that broad reach.”

The collaboration launches as Zillow Preview has already achieved significant scale. More than 400 brokerage partners — including Keller Williams, RE/MAX, Leading Real Estate Companies of the World®, HomeServices of America, Berkshire Hathaway HomeServices, United Real Estate, Engel & Völkers and Side — are enrolled in Zillow Preview, with listing creation continuing to grow.

A more complete search on both platforms
Preview listings are clearly labeled and receive enhanced visibility in search results and email alerts on both Zillow and Realtor.com®.

Once a buyer finds a Zillow Preview or Realtor.com® Preview home, they can:

Save it to stay updated as more details become availableContact the listing agent to get questions answered quicklyPre-book a tour to be one of the first in the door when the home is ready for showingsUse the extra time to connect with a buyer’s agent and get pre-approved for a mortgage — so they’re ready to act the moment the home goes live

Nearly 9 in 10 Americans (88%) say they would be at least somewhat interested in viewing pre-listed homes online if they were buying, according to a Zillow survey conducted by the Harris Poll.

A bigger stage for sellers and their agents
For sellers, the collaboration delivers pre-market exposure at a scale that wasn’t previously possible. Zillow and Realtor.com® together reach three-quarters of major portal visitors, according to Comscore data. Preview listings receive 18% more views, 9% more shares and 7% more saves than comparable listings during the first 14 days on market.

While sellers prepare their homes for sale, agents can build demand across both platforms simultaneously, turning the time before listing day into a marketing runway. Real buyer behavior during the Preview window — views, saves, tour requests — gives sellers and their agents pricing intelligence before a home officially launches on the MLS. Eighty-five percent of soon-to-be sellers say they’d be more likely to hire an agent who can pre-market their home to the broadest online audience.

As part of this collaboration, agents will receive the same benefits for both their Zillow Preview and Realtor.com® Preview listings, available at no cost to sellers or agents participating through an enrolled brokerage.

Participating agents receive three key benefits:

Greater visibility: Preview listings receive elevated placement in search results and saved-home alerts during the Preview period on both Zillow and Realtor.com®, helping more buyers discover the home earlier in the listing process.Free connections based on buyer choice: Consumers have the choice to connect with the listing agent or with a local buyer’s agent, depending on their needs. When a buyer reaches out to the listing agent directly through Zillow or Realtor.com®, those connections are free for the listing agent.Revenue participation: If a qualified Preview connection from either a Zillow Preview or Realtor.com® Preview home results in a closed transaction through a qualified partner agent, the listing agent may receive a share of the revenue earned from that transaction, settled through their brokerage. This fee does not increase consumers’ or agents’ costs. As always, commissions remain negotiable between consumers and the agents representing them.

About Zillow Group: 
Zillow Group, Inc. (Nasdaq: Z and ZG) is reimagining real estate to make home a reality for more and more people.

As the most visited real estate app and website in the United States, Zillow connects hundreds of millions of consumers with innovative technology, trusted agents and loan officers, and seamless digital solutions. With industry-leading tools and resources, Zillow supercharges real estate professionals so they can grow their businesses and deliver exceptional client experiences. For renters and housing providers, Zillow offers not only a robust marketplace but a set of end-to-end products and services to streamline applications, leases, payments and more.

Zillow’s ecosystem spans the entire home journey — from dreaming and shopping to renting, buying, selling and financing.

Zillow Group’s affiliates, subsidiaries and brands include Zillow®, Zillow Premier Agent®, Zillow Home Loans®, Zillow Rentals®, Zillow® New Construction, Trulia®, StreetEasy®, Out East®, HotPads®, Follow Up Boss®, ShowingTime® and dotloop®.

All marks herein are owned by MFTB Holdco, Inc., a Zillow affiliate. Zillow Home Loans, LLC is an Equal Housing Lender, NMLS #10287 (www.nmlsconsumeraccess.org). © 2026 MFTB Holdco, Inc., a Zillow affiliate.

About Realtor.com®
For over 30 years, Realtor.com® has connected buyers, sellers, and renters with trusted insights, professional guidance and powerful tools to help them find their perfect home. Recognized as the No. 1 real estate site REALTOR® agents recommend, Realtor.com® delivers consumer connections and a robust suite of marketing tools to support business growth. Realtor.com® is operated by News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV] subsidiary Move, Inc.

(ZFIN)

View original content to download multimedia:https://www.prnewswire.com/news-releases/zillow-preview-listings-are-now-live-on-realtorcom-offering-the-same-early-access-on-the-two-most-visited-real-estate-platforms-in-the-country-302881543.html

SOURCE Zillow

Continue Reading

Trending